Saranya Chumsri, M.D.

Saranya Chumsri, M.D., is a graduate of the top medical school, Chulalongkorn University in Bangkok, Thailand. She trained in internal medicine at the Albert Einstein Medical Center as well as Hematology and Oncology at the University of Maryland. With over 63 publications, Dr. Chumsri is an expert in breast cancer research. Her research is focusing on several aspects of breast cancer, including genomics, immunologic, epigenetics, breast cancer stem cells, endocrine resistance, as well as an aggressive form of breast cancer lacking estrogen receptor, progesterone receptor, and HER2, termed triple negative breast cancer. Dr. Chumsri also is an expert in developing genomic biomarkers, using RNA-seq and NanoString technologies, to predict response to targeted therapy in breast cancer, particularly immune related biomarkers, as well as to identify mechanisms of resistance to targeted therapy. Furthermore, she also developed multiple novel experimental therapeutics in breast cancer through phase I and II clinical trials with specific focus on immunotherapy, cancer vaccines, triple negative breast cancer, and endocrine resistant breast cancer. Combinatorial studies to evaluate the benefit of combining novel therapies in both preclinical and clinical trials.

Dr. Chumsri was awarded to participate in the AACR/ASCO Methods in Clinical Cancer Research (Vail Workshop) in 2007 and Molecular Biology in Clinical Oncology (Aspen Workshop) in 2008. She also received a prestigious Career Catalyst Research Grant from Susan G. Komen for the Cure. Dr. Chumsri is the national PI for several clinical trials. In 2019, Dr. Chumsri also received the Outstanding Research Award by Department of Medicine at Mayo Clinic Florida.

As a part of her focus on breast cancer research, Dr. Chumsri is a clinician scientist reviewer for the Breast Cancer Research Program (BCRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP). She was also the Co-leader disease-oriented group: breast cancer for the University of Chicago Phase II Consortium (P2C) between 2011-2014. Furthermore, Dr. Chumsri also receives several funding supports from the Department of Defense, National Cancer Institute, Foundations, and pharmaceutical companies to conduct novel clinical trials in Immuno Oncology as well as Cancer Vaccine for both treatment and prevention of breast cancer. Currently, Dr. Chumsri is serving as the leader in the Experimental Trials for Precision Medicine at the Jacoby Center for Breast Health at Mayo Clinic Florida. Dr. Chumsri also serve in several important committees at Mayo Clinic Florida, including Cancer Center Scientific Progress Review Subcommittee, Fellowship Program Education Committee, and Clinical Trials Leadership Council. Moreover, Dr. Chumsri is on multiple international steering committees, including (Neo)ALTTO steering committee, ACCRU Consortium Breast Cancer Committee, and the Alliance for Clinical Trials in Oncology Immuno-Oncology Committee.